BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy

  September 10, 2025

   · 

  6 min read
• Press Releases

  Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

  September 10, 2025

   · 

  7 min read
• Press Releases

  Aphaia Pharma Initiates Second Phase 2 Trial of Oral Candidate in Obesity

  September 10, 2025

   · 

  3 min read
• Press Releases

  Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

  September 10, 2025

   · 

  8 min read
• Press Releases

  Elutia Announces Sale of BioEnvelope Business to Boston Scientific Corporation for $88 Million

  September 10, 2025

   · 

  6 min read
• Press Releases

  Metaphore Biotechnologies Expands Executive Leadership Team with Appointment of Anabella Villalobos as Chief Scientific Officer

  September 10, 2025

   · 

  2 min read
• Press Releases

  Pfizer’s PREVNAR 20 Selected for Pneumococcal Public Immunization Program in British Columbia

  September 10, 2025

   · 

  4 min read
• Press Releases

  Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

  September 10, 2025

   · 

  10 min read
• Press Releases

  NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

  September 10, 2025

   · 

  12 min read
• Press Releases

  Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

  September 10, 2025

   · 

  4 min read